ReviewImmunologic research2014
New treatments for inflammatory rheumatic disease.
Review in Immunologic research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Inflammatory rheumatic diseases and the risk of Parkinson's disease: A systematic review and meta-analysis.Frontiers in neurology · 2022Pooled it
- Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTHClinical pharmacology in drug development · 2022Trial
- Expansion of inflammatory monocytes in periphery and infiltrated into thyroid tissue in Graves' disease.Scientific reports · 2021Trial
- RepurposingACS omega · 2026Article
- Does the Use of Denosumab in Combination with bDMARDs or tsDMARDs Increase the Risk of Infection in Patients with Osteoporosis and Inflammatory Rheumatic Diseases?Journal of clinical medicine · 2025Article
- Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases.Journal of clinical medicine · 2023Review
- Methylprednisolone PromotesMicroorganisms · 2023Article
- Association between serum uric acid levels and peripheral artery disease in Chinese adults with hypertension.Frontiers in endocrinology · 2023Article
- Flare of adult-onset Still's disease following mRNA COVID-19 vaccination: a case report and review of literature.Clinical rheumatology · 2022Review
- Regulatory Role of miRNAs and lncRNAs in Gout.Computational and mathematical methods in medicine · 2022Article
- Treatment of Autoimmune Diseases with Therapeutic Antibodies: Lessons Learned from PID Patients Allow for Stratification of the Infection Risk.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease.Diagnostics (Basel, Switzerland) · 2021Review
- Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea.Archives of rheumatology · 2021Article
- Inhibitory Effect of Black Radish (Preventive nutrition and food science · 2020Article
- Article
- Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis.Drug design, development and therapy · 2019Article
- Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients.Scientific reports · 2018Article
- Clinical Challenges: Identification of Patients With Novel Primary Immunodeficiency Syndromes.Journal of pediatric hematology/oncology · 2018Article
- Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability.Experimental biology and medicine (Maywood, N.J.) · 2017Review
- Ethyl Caffeate Ameliorates Collagen-Induced Arthritis by Suppressing Th1 Immune Response.Journal of immunology research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As our understanding of the pathogenesis of autoimmune diseases is growing, new therapies are being developed to target disease-specific pathways. Since the introduction of etanercept in 1998, several biotechnological agents have been developed, most of them indicated in the treatment of rheumatoid arthritis, but also psoriatic arthritis. Most currently available molecules target TNF-alfa with different strategies (i.e., etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol), IL-6 (tocilizumab), CTLA-4 (abatacept), and B cells (rituximab, belimumab) as they are key mediators in the cascade of inflammation. Further, small molecules have been recently developed to target intracellular signaling, such as Janus Kinases for tofacitinib, the first FDA-approved small molecule for rheumatoid arthritis. Most novel treatments are being developed for arthritis with specific differences between rheumatoid and psoriatic arthritis, as well as for systemic lupus erythematosus, following the approval of belimumab. Finally, biologic therapies are effective also in gout, mainly targeting interleukin-1 to block the inflammasome. This review article describes the new and upcoming treatment options for rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and gout to dissect what we should be aware of when discussing these new and promising molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.